BOSTON and SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological and psychiatric disorders, today announced that management plans to present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 11:15 a.m. PST / 2:15 p.m. EST. A live and archived webcast of the pr ...

公司资本结构优化行动 - 公司通过自愿转换方式，清偿了约31.1万美元的未偿债务，将其转换为公司普通股 [1] - 此次交易旨在减少公司债务及未来利息支出，并简化其资本结构 [2] - 首席执行官表示，此举是清理资产负债表过程中的一个审慎步骤，同时表明债权人选择成为股东是对公司创造价值的信心体现 [3] 公司战略与业务模式 - 公司战略为收购盈利的专业营销机构，并将其接入共享技术平台，利用人工智能使营销活动更智能高效 [4] - 公司是一个人工智能驱动的营销平台和代理网络，通过结合人类专业知识与机器智能，帮助品牌预测高价值客户并实时优化营销活动以增加收入 [5] - 公司平台整合了专业机构和专有分析工具，旨在构建一个服务于中型市场品牌的规模化人工智能营销平台 [3] - 公司正积极收购更多机构，以扩展其平台、深化能力并加速增长 [6] 近期整合与未来展望 - 此次债务转换紧随JUICE和Retina的收购交易，显示出对公司整合与扩张计划的信心 [3] - 公司专注于在构建一体化人工智能驱动营销生态系统的过程中更有效地利用其资产负债表 [3] - 公司预计将继续探索改善资本结构的机会，同时投资于技术、整合及未来的网络内收购 [4] - 每项收购在整合到平台后都会变得更有价值，在执行该战略的同时减少债务使公司长期处于更有利地位 [4]

CHASKA, Minn., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has been notified by Nasdaq that the company’s stock is expected to be added to the Nasdaq Biotech Index (NASDAQ: NBI) as part of the annual reconstitution of the 2025 Nasdaq indexes. Lifecore’s inclusion in the Nasdaq Biotech Index will be effective prior to market open on Monday, December 22, 2025. T ...

Company Awarded Extension to Existing Supply Tender Relating to its Portfolio of Four Specialty Plasma-Derived ProductsSupply Extension Secures Ongoing Sales of Approximately $5.0-$7.0 Million Per Year for the Period Between Q2-26 and Q1-28Kamada Reiterates its 2025 Full-Year Revenue Guidance of $178 Million-$182 Million and Adjusted EBITDA of $40 Million-$44 MillionKamada Projects Double-Digit Growth in Revenues and Profitability in 2026; Detailed Guidance to be Provided in January 2026 REHOVOT, Israel, an ...

SEATTLE, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that Thijs Spoor, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Wednesday, January 14, 2026, at 2:15 p.m. PT. 44th Annual J.P. Morgan Healthcare Conference – Company PresentationDate: Wednes ...

Prescription pharmaceutical transdermal fentanyl is a valuable treatment for management of pain in opioid-tolerant patients, severe enough to require daily, around-the-clock, long-term opioid treatment for which alternate treatment options are inadequate. Illicit fentanyl and its core precursor chemicals have been designated as weapons of mass destruction to enable the US government to combat the manufacture and distribution by cartels and foreign networks that have flooded the US with illegal fentanyl. Nut ...

Q1 GAAP revenues of $607.6 million, up 6.9% from Q1 2025.Organic ASV was $2,389.6 million at November 30, 2025, up 5.9% year over year.Q1 GAAP operating margin of 31.6%, down approximately 200 bps year over year.Q1 adjusted operating margin of 36.2%, down 137 bps year over year.Q1 GAAP diluted EPS of $4.06, up 4.4% from the prior year, and Q1 adjusted diluted EPS of $4.51, up 3.2% year over year.FactSet's Board of Directors approved an increase to the existing share repurchase authorization from $400 millio ...

TORONTO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Talisker Resources Ltd. (“Talisker” or the “Company”) (TSX: TSK, OTCQX: TSKFF) announces that further to the Company’s news release of December 17, 2025, the Company has successfully reduced staffing levels at the Bralorne Mine in accordance with its Emergency Response Plan in response to restricted site access caused by an extreme rainfall event in the region. All but 16 critical personnel drove out via Highway 40 which was temporarily opened to facilitate the wit ...

The combination of denifanstat and resmetirom was generally well-toleratedPharmacokinetic (PK) results support further development of the combinationA Phase 2 trial of a denifanstat/resmetirom combination in F4 MASH patients is planned to initiate in 2H 2026 SAN MATEO, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced positive resu ...

TORONTO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- NorthWest Copper Corp. (“NorthWest” or the “Company”) (TSX-V: NWST) is pleased to report drill results from two holes completed as part of its 2025 program at the Company’s 100% owned Kwanika project in British Columbia. Both holes returned higher-grade1 results, highlighted by an intercept in hole K-25-283 within the Central Zone of 43 metres grading 1.83% Cu and 1.28g/t Au (3.01% copper equivalent2, “CuEq”), and a significant near-surface intercept in K-25-273 of ...